정밀 종양학 기술 시장 : 시장 분석 및 예측 - 유형별, 제품별, 서비스별, 기술별, 용도별, 최종 사용자별, 컴포넌트별, 전개 모드별, 단계별(-2035년)

Precision Oncology Technologies Market is anticipated to expand from $114.0 Billion in 2024 to $302.1 Billion by 2034, growing at a CAGR of approximately 9%. The Precision Oncology Technologies Market encompasses advanced diagnostic and therapeutic tools tailored to individual cancer profiles, integrating genomics, proteomics, and bioinformatics. These technologies enable personalized treatment plans, improving patient outcomes by targeting unique genetic mutations. Rapid advancements in molecular diagnostics and increased investment in cancer research are propelling market growth, highlighting opportunities in biomarker discovery and targeted therapies.

The Precision Oncology Technologies Market is significantly influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea are bolstering their domestic capabilities in response to trade tensions, aiming to reduce dependency on foreign technologies. China is accelerating its investment in homegrown precision oncology solutions, driven by both geopolitical factors and a robust healthcare agenda. Taiwan, pivotal in semiconductor supply, faces geopolitical vulnerabilities yet remains indispensable. The global market for precision oncology is witnessing robust growth, driven by technological advancements and rising cancer prevalence. By 2035, the market is expected to evolve with increased regional collaborations and innovation. Middle East conflicts may indirectly affect the market through energy price volatility, influencing operational costs and supply chain stability.

The Precision Oncology Technologies Market is evolving rapidly, propelled by advancements in personalized cancer treatment and genomic profiling. Within the diagnostics segment, genetic testing emerges as the top-performing sub-segment, driven by its ability to identify specific mutations and guide targeted therapies. Liquid biopsy technologies follow closely, offering non-invasive options for monitoring disease progression and treatment response. In the therapeutics segment, targeted therapy leads, leveraging molecular insights to develop drugs that precisely attack cancer cells. Immunotherapy, particularly checkpoint inhibitors, represents the second highest-performing sub-segment, reflecting its transformative impact on cancer care.

The integration of artificial intelligence in precision oncology is gaining momentum, enhancing diagnostic accuracy and treatment personalization. AI-driven platforms for data analysis and predictive modeling are becoming indispensable tools for oncologists. Collaboration between biotech firms and research institutions is fostering innovation, accelerating the development of novel therapeutics and diagnostic approaches. Investment in precision oncology technologies is expected to continue, driven by the promise of improved patient outcomes and reduced healthcare costs.

The Precision Oncology Technologies Market is characterized by a dynamic interplay of market share, pricing strategies, and new product introductions. Leading companies are focusing on innovative solutions that enhance diagnostic accuracy and treatment efficacy. Pricing remains competitive, influenced by technological advancements and the demand for personalized cancer therapies. New product launches are frequent, reflecting the sector's commitment to addressing unmet medical needs and improving patient outcomes. The market is buoyed by the increasing prevalence of cancer and the growing emphasis on precision medicine.

In terms of competition, key players are continuously benchmarking against each other to maintain a competitive edge. Regulatory influences are significant, with stringent guidelines shaping product development and approval processes. The market landscape is further influenced by strategic alliances and collaborations, enhancing research capabilities and market reach. North America and Europe are at the forefront of regulatory standards, while emerging markets in Asia-Pacific are rapidly adopting precision oncology technologies. The integration of artificial intelligence and genomics is poised to revolutionize the market, offering substantial growth prospects.

Geographical Overview:

The Precision Oncology Technologies Market is witnessing a dynamic expansion across various regions, each contributing uniquely to its growth. North America leads, driven by advanced healthcare infrastructure and substantial investments in precision medicine research. The presence of major biotech firms accelerates technological advancements, enhancing the region's market dominance. In Europe, robust government initiatives supporting personalized medicine and a strong focus on research and development are propelling market growth.

The region's emphasis on regulatory frameworks also fosters a conducive environment for innovation. In the Asia Pacific, the market is burgeoning, fueled by increasing cancer prevalence and rising healthcare expenditures. Countries like China and India are emerging as significant players, driven by technological advancements and growing awareness of precision oncology. Latin America and the Middle East & Africa are gradually recognizing the potential of precision oncology technologies. These regions are witnessing increased investments and collaborations, paving the way for future growth and innovation.

Recent Developments:

The Precision Oncology Technologies Market has experienced notable developments in recent months. Roche announced a strategic partnership with Illumina to enhance its precision oncology offerings, focusing on integrating genomic sequencing technologies to optimize cancer treatment strategies. This collaboration aims to accelerate the development of personalized cancer therapies.

In another significant move, Thermo Fisher Scientific completed the acquisition of a leading genomic diagnostics company, augmenting its capabilities in precision oncology. This acquisition is expected to bolster Thermo Fisher's portfolio, enabling more comprehensive diagnostic solutions for oncology patients.

Meanwhile, Guardant Health launched an innovative liquid biopsy test designed to provide real-time insights into tumor genetics, offering a less invasive alternative to traditional biopsies. This product launch is anticipated to revolutionize cancer diagnostics by enhancing the precision of treatment decisions.

On the regulatory front, the U.S. FDA has introduced new guidelines to expedite the approval process for precision oncology drugs, aiming to bring innovative treatments to market more swiftly. This regulatory shift is likely to stimulate further advancements in the sector.

Financially, the precision oncology market has attracted substantial investment, with venture capital firms injecting significant funds into startups specializing in AI-driven oncology solutions. This influx of capital underscores the market's potential and the growing interest in leveraging technology to transform cancer care.

Key Trends and Drivers:

The Precision Oncology Technologies Market is experiencing robust expansion, fueled by several key trends and drivers. A significant trend is the advancement of genomic sequencing technologies, enabling more precise identification of cancer mutations, which is crucial for personalized treatment plans. This technological progress is making precision oncology more accessible and cost-effective.

Another trend is the growing collaboration between pharmaceutical companies and technology firms. These partnerships are accelerating the development and commercialization of innovative diagnostic tools and treatments. Furthermore, the integration of artificial intelligence and machine learning in oncology is enhancing predictive analytics, leading to improved patient outcomes and treatment efficiency.

Drivers of this market include the increasing prevalence of cancer worldwide, prompting a demand for more targeted and effective therapies. Governments and healthcare institutions are investing heavily in precision medicine initiatives, recognizing their potential to revolutionize cancer treatment. The rise of patient-centric care models is also driving the adoption of precision oncology, as patients and healthcare providers seek tailored treatment options that improve quality of life and survival rates. With these trends and drivers, the Precision Oncology Technologies Market is poised for substantial growth, offering lucrative opportunities for stakeholders.

Restraints and Challenges:

The Precision Oncology Technologies Market is confronted with several significant restraints and challenges. Firstly, the high cost of precision oncology treatments and technologies restricts their accessibility, particularly in low-income regions. This financial barrier hinders widespread adoption and limits patient access to cutting-edge therapies. Secondly, the complexity and variability of cancer genomics present challenges in data interpretation and clinical decision-making. This complexity demands highly specialized expertise, which is not always readily available. Thirdly, regulatory hurdles and lengthy approval processes for new technologies can delay market entry and innovation. These regulatory challenges can stifle the pace of technological advancement. Fourthly, there is a lack of standardized protocols for precision oncology, leading to inconsistencies in treatment outcomes. This absence of standardization complicates the integration of precision oncology into routine clinical practice. Lastly, the need for robust data privacy and security measures is critical, as sensitive patient information is integral to precision oncology. Ensuring compliance with data protection regulations remains a formidable challenge.

Key Companies:

Guardant Health, Foundation Medicine, Caris Life Sciences, Tempus, Natera, Neo Genomics, Personalis, Adaptive Biotechnologies, Biodesix, Invitae, Onco Cyte, Freenome, Grail, Helix, Bristol Myers Squibb, Illumina, Strata Oncology, Genomic Health, Oncocyte Corporation, Epic Sciences

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Component
• 2.8 Key Market Highlights by Deployment
• 2.9 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Diagnostics
  • 4.1.2 Therapeutics
  • 4.1.3 Prognostics
  • 4.1.4 Predictive Biomarkers
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Genetic Tests
  • 4.2.2 Companion Diagnostics
  • 4.2.3 Liquid Biopsy
  • 4.2.4 Next-Generation Sequencing
  • 4.2.5 Immunohistochemistry
  • 4.2.6 Fluorescence In Situ Hybridization
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Consultation
  • 4.3.2 Genomic Profiling
  • 4.3.3 Data Interpretation
  • 4.3.4 Clinical Trial Services
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Gene Sequencing
  • 4.4.2 Polymerase Chain Reaction
  • 4.4.3 Microarray
  • 4.4.4 Bioinformatics
  • 4.4.5 Nanotechnology
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Breast Cancer
  • 4.5.2 Lung Cancer
  • 4.5.3 Colorectal Cancer
  • 4.5.4 Prostate Cancer
  • 4.5.5 Melanoma
  • 4.5.6 Leukemia
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Diagnostic Laboratories
  • 4.6.3 Research Institutes
  • 4.6.4 Pharmaceutical Companies
  • 4.6.5 Biotechnology Firms
• 4.7 Market Size & Forecast by Component (2020-2035)
  • 4.7.1 Software
  • 4.7.2 Hardware
  • 4.7.3 Reagents
  • 4.7.4 Kits
  • 4.7.5 Consumables
• 4.8 Market Size & Forecast by Deployment (2020-2035)
  • 4.8.1 On-Premises
  • 4.8.2 Cloud-Based
  • 4.8.3 Hybrid
• 4.9 Market Size & Forecast by Stage (2020-2035)
  • 4.9.1 Early-Stage Cancer
  • 4.9.2 Advanced-Stage Cancer
  • 4.9.3 Recurrent Cancer

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Component
    • 5.2.1.8 Deployment
    • 5.2.1.9 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Component
    • 5.2.2.8 Deployment
    • 5.2.2.9 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Component
    • 5.2.3.8 Deployment
    • 5.2.3.9 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Component
    • 5.3.1.8 Deployment
    • 5.3.1.9 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Component
    • 5.3.2.8 Deployment
    • 5.3.2.9 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Component
    • 5.3.3.8 Deployment
    • 5.3.3.9 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Component
    • 5.4.1.8 Deployment
    • 5.4.1.9 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Component
    • 5.4.2.8 Deployment
    • 5.4.2.9 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Component
    • 5.4.3.8 Deployment
    • 5.4.3.9 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Component
    • 5.4.4.8 Deployment
    • 5.4.4.9 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Component
    • 5.4.5.8 Deployment
    • 5.4.5.9 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Component
    • 5.4.6.8 Deployment
    • 5.4.6.9 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Component
    • 5.4.7.8 Deployment
    • 5.4.7.9 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Component
    • 5.5.1.8 Deployment
    • 5.5.1.9 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Component
    • 5.5.2.8 Deployment
    • 5.5.2.9 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Component
    • 5.5.3.8 Deployment
    • 5.5.3.9 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Component
    • 5.5.4.8 Deployment
    • 5.5.4.9 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Component
    • 5.5.5.8 Deployment
    • 5.5.5.9 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Component
    • 5.5.6.8 Deployment
    • 5.5.6.9 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Component
    • 5.6.1.8 Deployment
    • 5.6.1.9 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Component
    • 5.6.2.8 Deployment
    • 5.6.2.9 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Component
    • 5.6.3.8 Deployment
    • 5.6.3.9 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Component
    • 5.6.4.8 Deployment
    • 5.6.4.9 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Component
    • 5.6.5.8 Deployment
    • 5.6.5.9 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Guardant Health
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Foundation Medicine
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Caris Life Sciences
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Tempus
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Natera
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Neo Genomics
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Personalis
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Adaptive Biotechnologies
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Biodesix
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Invitae
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Onco Cyte
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Freenome
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Grail
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Helix
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Bristol Myers Squibb
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Illumina
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Strata Oncology
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Genomic Health
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Oncocyte Corporation
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Epic Sciences
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us